Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Torella

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Hepatology (Baltimore, Md.)|March 4, 2022
mRNA and gene editing: Late breaking therapies in liver diseasesNerea Zabaleta, Laura Torella, Nicholas D Weber, et al.
FEBS Letters|July 30, 2024
Gene editing in liver diseasesLaura Torella, Nerea Santana-Gonzalez, Nerea Zabaleta, et al.
Case Reports in Genetics|August 30, 2018
A Rare Case of Severe Congenital RYR1-Associated MyopathyNicola Laforgia, Manuela Capozza, Lucrezia De Cosmo, et al.
Plos Pathogens|May 13, 2024
Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in miceGracián Camps, Sheila Maestro, Laura Torella, et al.
Kidney International Reports|February 24, 2025
CKD in Bardet-Biedl Syndrome: Evidence Supporting Multifactorial EtiologyMiriam Zacchia, Floriana Secondulfo, Andrea Melluso, et al.
Frontiers in Cellular and Infection Microbiology|July 5, 2022
Differential Trafficking and Expression of PIR Proteins in Acute and Chronic <i>Plasmodium</i> InfectionsMaria Giorgalli, Deirdre A Cunningham, Malgorzata Broncel, et al.
Molecular Therapy. Methods & Clinical Development|December 9, 2020
<i>In Vitro</i> and <i>In Vivo</i> Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9Sergio López-Manzaneda, Isabel Ojeda-Pérez, Nerea Zabaleta, et al.
Nature Communications|December 22, 2018
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type INerea Zabaleta, Miren Barberia, Cristina Martin-Higueras, et al.
EMBO Molecular Medicine|January 5, 2024
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1Laura Torella, Julia Klermund, Martin Bilbao-Arribas, et al.
Frontiers in Genome Editing|November 19, 2025
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)María Ortiz-Bueno, Iris Ramos-Hernández, Luis Algeciras-Jiménez, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Hepatology (Baltimore, Md.)|March 4, 2022
mRNA and gene editing: Late breaking therapies in liver diseasesNerea Zabaleta, Laura Torella, Nicholas D Weber, et al.
FEBS Letters|July 30, 2024
Gene editing in liver diseasesLaura Torella, Nerea Santana-Gonzalez, Nerea Zabaleta, et al.
Case Reports in Genetics|August 30, 2018
A Rare Case of Severe Congenital RYR1-Associated MyopathyNicola Laforgia, Manuela Capozza, Lucrezia De Cosmo, et al.
Plos Pathogens|May 13, 2024
Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in miceGracián Camps, Sheila Maestro, Laura Torella, et al.
Kidney International Reports|February 24, 2025
CKD in Bardet-Biedl Syndrome: Evidence Supporting Multifactorial EtiologyMiriam Zacchia, Floriana Secondulfo, Andrea Melluso, et al.
Frontiers in Cellular and Infection Microbiology|July 5, 2022
Differential Trafficking and Expression of PIR Proteins in Acute and Chronic <i>Plasmodium</i> InfectionsMaria Giorgalli, Deirdre A Cunningham, Malgorzata Broncel, et al.
Molecular Therapy. Methods & Clinical Development|December 9, 2020
<i>In Vitro</i> and <i>In Vivo</i> Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9Sergio López-Manzaneda, Isabel Ojeda-Pérez, Nerea Zabaleta, et al.
Nature Communications|December 22, 2018
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type INerea Zabaleta, Miren Barberia, Cristina Martin-Higueras, et al.
EMBO Molecular Medicine|January 5, 2024
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1Laura Torella, Julia Klermund, Martin Bilbao-Arribas, et al.
Frontiers in Genome Editing|November 19, 2025
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)María Ortiz-Bueno, Iris Ramos-Hernández, Luis Algeciras-Jiménez, et al.
Pageof 2